Pizuglanstat

Pizuglanstat (Compound 3; TAS-205 free base) is an orally active prostaglandin D synthase inhibitor with an IC50 of 76 nM for human hematopoietic prostaglandin D synthase. Pizuglanstat inhibits the synthesis of PGD2. Pizuglanstat improves experimental allergic rhinitis. Pizuglanstat can be used in the study of muscle regenerative diseases such as muscular dystrophy[1][2][3].

Product Specifications

CAS Number

[1244967-98-3]

Product Name Alternative

TAS-205 (free base)

UNSPSC

12352005

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/pizuglanstat.html

Purity

99.70

Solubility

DMSO : 12.5 mg/mL (ultrasonic)

Smiles

O=C(N1CCOCC1)C2CCN(C3=CC=C(NC(N4CCN(C(C5=CC=CN5C)=O)CC4)=O)C=C3)CC2

Molecular Formula

C27H36N6O4

Molecular Weight

508.61

References & Citations

[1]Yoshihiro Urade, et al. Piperazine compound capable of inhibiting prostaglandin D synthase. United States. US8865714B2. 2010-03-08.|[2]Aoyagi H, et al. Potential synergistic effects of novel hematopoietic prostaglandin D synthase inhibitor TAS-205 and different types of anti-allergic medicine on nasal obstruction in a Guinea pig model of experimental allergic rhinitis. Eur J Pharmacol. 2020 May 15;875:173030.|[3]Komaki H, et al. Early phase 2 trial of TAS-205 in patients with Duchenne muscular dystrophy. Ann Clin Transl Neurol. 2020 Feb;7 (2) :181-190.